CA-PICSART
6.4.2021 14:02:11 CEST | Business Wire | Press release
PicsArt , the world’s largest creative platform, today announced the opening of its newest office in the U.K. Headquartered in San Francisco, PicsArt’s workforce spans the globe with growing offices and employees in Yerevan, Armenia, Los Angeles, Moscow, Beijing, Tokyo and India. In the past year alone, PicsArt has expanded its employee headcount by 36%. Establishing a new office in the U.K. is PicsArt’s latest move in its strategy to meet the needs of its user base of more than 150 million monthly active creators worldwide.
The announcement follows PicsArt’s recent hiring of its VP of Design, acclaimed designer Duncan Riley, who is based in the U.K. In this role, Riley will lead the expansion of the new hub, which will be focused on Product Development and Design. Riley brings more than 18 years of experience growing creative teams and crafting global user experiences for a host of leading brands, including Shazam, Skyscanner, Snapchat, NBCUniversal, Viacom, Absolute Radio and more.
“At PicsArt we are building the best all-round creator experience possible, allowing anyone and everyone to perfect their everyday moments, express their passions, promote their business, or even create art. I'm excited to get started with the incredible talent here at PicsArt, and begin growing the UK-based team to support our vision in 2021,” Riley shared.
Of the buildout, PicsArt founder and CEO Hovhannes Avoyan says, “As a globally-minded and operated company of more than 700 employees, our goal is to best serve the many ways PicsArt creators use our product across the world. We are excited to come to the U.K. and welcome new members and all of their insights and contributions to build amazing things together for our active and dynamic user base.”
In addition to hiring for its new U.K. hub, PicsArt is actively hiring in other global regions - including remote-based positions - in design, engineering, product operations, marketing, content, and more. For more information on current open roles, prospective applicants can visit https://picsart.com/jobs .
About PicsArt
PicsArt is the world’s #1 creative platform and a top 20 most downloaded app for seven consecutive quarters. Every month, the PicsArt community creates, remixes and shares billions of visual stories using the company’s powerful and easy-to-use editing tools. PicsArt has amassed one of the largest open-source content collections in the world, including free-to-edit photos, stickers, backgrounds, templates and more. PicsArt is available in 30 languages for free and as a subscription on iOS, Android and Windows devices. PicsArt is backed by Sequoia Capital, DCM Ventures, Insight Partners, and Siguler Guff & Company. Download the app or visit picsart.com or picsart.com/brands/ for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005093/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom